Back to Top Skip to main content Skip to sub-navigation

DHA contributes to COVID-19 vaccine effort

Vaccine bottles A potential COVID-19 vaccine is currently in the testing stage in New Orleans, Louisiana. (Photo courtesy of Johnson & Johnson.)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

The Department of Defense is prioritizing a joint effort to protect DOD personnel and their families by developing, distributing, and subsequently administering a Federal Drug Administration-approved vaccine to reduce COVID-19-related illnesses, hospitalizations, and deaths. This effort is critical to the strategy of helping restore societal functioning and maintain military readiness to defend the nation and its interests.

While Pfizer’s vaccine is being distributed to all U.S. jurisdictions for administration, several more candidates are in development and clinical trials continue to be conducted simultaneously with pharmaceutical partners. The Defense Health Agency’s Immunization Healthcare Division (IHD) is contributing to the investigative effort by providing study sites at military medical treatment facilities and clinical trial centers for AstraZeneca’s Phase III trials.

Following FDA’s emergency use authorization on Dec. 12 to distribute Pfizer’s vaccine, DOD initiated its planned, standardized, and coordinated strategy to prioritize, distribute, and administer its initial allocation of just under 44,000 vaccines to prioritized DOD personnel. Emergency department and Intensive Care Unit healthcare workers in 16 designated locations will receive the vaccines from this initial allotment, but the vaccination effort will extend on a rolling basis to approximately 11.1 million DOD personnel. The DOD will have an independent, but collaborative, program with the U.S. Department of Health and Human Services and the Center for Disease Control to provide COVID-19 vaccines to DoD uniformed service members, both the active and Selected Reserve components, including members of the National Guard; dependents; retirees; civilian employees, and selected DoD contract personnel as authorized in accordance with DoD regulation.

The Department’s priorities are protecting our Service members, DoD civilians, and families; safeguarding our national security capabilities; and supporting the whole-of-nation response to the COVID-19 pandemic.

Military building with sign that says "OWS Vaccine Trial Here"
The entrance to the patient testing facility of the Operation Warp Speed vaccine trial at Joint Base San Antonio-Lackland, Texas. Operation Warp Speed is a partnership to accelerate the development, manufacturing, and distribution of COVID-19 vaccines. (Photo by Airman 1st Class Melody Bordeaux/59th Medical Wing.)

The DoD will have an independent, but collaborative, program with the U.S. Department of Health and Human Services (HHS) and the Center for Disease Control (CDC) to provide COVID-19 vaccines to DoD uniformed service members, both the active and Selected Reserve components, including members of the National Guard; dependents; retirees; civilian employees, and selected DoD contract personnel as authorized in accordance with DoD regulation. The Department’s priorities are protecting our Service members, DoD civilians, and families; safeguarding our national security capabilities; and supporting the whole-of-nation response to the COVID-19 pandemic.

Dr. Limone Collins, Jr., chief of vaccine safety and evaluation at IHD, talked to MHS about the development and clinical trials process of the vaccines.

MHS: What role has IHD had in the COVID-19 vaccine development?

Collins: This is a collaborative effort consistent with how we do things within the DOD. It’s not just IHD – we had a contributory role, but this effort couldn’t have been accomplished without a number of folks within the DOD to make this happen. Our primary role in IHD is to serve as consultants and guides to immunizations within the DOD based on our knowledge and our familiarity with respective points of contact, the variety of military medical treatment facilities, and the procedure itself. It was based on our experience collaborating with the Infectious Disease Clinical Research Program out of the Uniformed Services University of the Health Sciences with a multi-site study looking at the effectiveness of the different types of the influenza vaccine that helped us, particularly within IHD as well as IDCRP, to really know the lay of the land and to help serve as consultants to make the DOD’s role in this even smoother.

MHS: How is a vaccine like this, to counter the SARS CoV2 virus, developed?

Collins: There are a variety of vaccine types but the primary types that have gone to EUA [emergency use authorization] are called messenger RNA [ribonucleic acid] (mRNA)-type vaccines. The DOD is involved with what is called a viral vector-based vaccine. The whole thought process is to see how we can manipulate the immune system to get the most effective vaccine. It has been taken up by a number of the manufacturers early on in the hypothesis to see what type of vaccine we are going to be looking at to try to accomplish the ultimate goal of having an effective vaccine.

MHS: How was it able to be developed so much faster than other vaccines?

Collins: There had been some research, particularly based on our experience with the Ebola vaccine and dealing with SARS [Severe Acute Respiratory Syndrome] and Ebola, so that was helpful. But there are also new constructs in regard to how we develop vaccines. The utilization of different technologies contributed to our ability to move at a more rapid rate, and the combination of the veering phases that we would generally go through also helps. It was a combination of all these things: newer technologies, looking at our past experience with similar organisms, as well as combining the typical phases that we generally go through.

MHS: How many steps/phases comprise a vaccine trial and what occurs in each?

Collins: The classic answer is that there are four phases. The first phase, which some folks call Phase 0, is when you start developing your hypothesis: What type of vaccine are we looking at? And that’s when you consider whether we’re going to have an inactivated vaccine, use the mRNA technology, or a viral-vector vaccine? What are we looking to accomplish with the vaccine we’re proposing? That is followed by looking at a smaller group of individuals, generally less than 100 healthy folks, to look at the safety of the particular vaccine. Then you go to the next step (Phase II), where you have a larger group of individuals, again looking at the safety and the effectiveness. Then you get to where most of the vaccine trials currently stand, which is Phase III, where you have a large trial of individuals (within the 30,000 or 40,000 range) focusing on the efficacy of the vaccines. That is followed by Phase IV, where you’ve done your large trials, sent it to the FDA for analysis and their determination that your vaccine has met all its goals and is an efficacious as well as an effective vaccine.

What most people don’t realize is that even after you get licensing by the FDA there is a follow-up period, what we call a post-surveillance activity, which basically continues with the evaluation of a vaccine or drug, where you continue to observe them for their safety precautions. This is particularly important because now you’re putting it into the general population, so it becomes even more important to look at whatever safety signals may come when you put it into that general population.

MHS: How long is that follow-up observation period once it’s distributed among the general population?

Collins: All those things were determined by the FDA during their analysis – they make the final decision on the length of the post-surveillance time period. There could be contributory information that the Advisory Committee on Immunization Practice may also try to solicit in regard to that post-surveillance time period.

MHS: What is the process of recruiting volunteers for vaccine trials?

Collins: That’s particularly important with regard to this vaccine. A lot of it is determined by the scientists of the manufacturers in their initial proposal. It’s particularly important for the COVID-19-related vaccines based on what we’re seeing in regard to the epidemiology, what’s happening with the disease manifestations, its morbidity and mortality.

MHS: Was there any special effort to include military service members to volunteer for the trials?

Collins: All the volunteers in the AstraZeneca trials, in which the DOD is participating, are DOD beneficiaries. When the company approached the DOD, we looked at who would be captured by our variety of military medical treatment facilities, so although the initial conversation considered folks outside DOD beneficiaries, in order to really help facilitate the logistics, such as access to military facilities, it was decided that we would focus primarily on DOD beneficiaries. Trying to incorporate individuals who didn’t have that usual access to our facilities or to onboarding our clinics, etc. would have been a bridge too far, particularly when considering the time frame we had, so that’s why it was limited to military service members.

MHS: When people hear in the news that a vaccine candidate is at 90 or 94 percent efficacy rate, what does that mean?

Collins: To put it in simple terms, it’s a percentage of reduction in disease in the vaccinated group versus or compared to those who are unvaccinated.

You have different arms: Individuals who were vaccinated with the product and individuals who were given a placebo. But it’s blinded, so neither the individuals nor the investigators know whether a particular volunteer is getting the vaccine or a placebo. Then, the individuals from both arms go out into their environment where there’s a potential for them to be exposed to COVID-19. The investigators then look at the number of people from the vaccinated group who got COVID-19 versus the number from the group that received the placebo that got COVID-19. For example, out of 100 people who were vaccinated maybe five got COVID-19 versus the group of 100 folks who got the placebo of which maybe 50 developed COVID-19. That’s how you do your comparison and arrive at the efficacy rates.

MHS: Does getting a vaccine prevent the person from contracting the disease, or does it cause their symptoms to be less severe if they get it, or both?

Collins: Now you understand precisely the importance of why we need multiple vaccines, because they work differently. It’s also why we need to continue to observe what occurs with each individual vaccine and the epidemiology.

What we think may happen is some of the vaccines may do more mitigating. For example, if you take a flu shot you may contract the virus, but abort the symptoms, that is, you may have milder symptoms such as fever or nasal congestion. In that circumstance, you mitigated some of the sequelae or symptoms associated with influenza the disease. That’s what we’ve seen periodically with utilizing a variety of the influenza vaccine, particularly. There are years where we have “better” flu years or seasons than others; that’s because the development of the influenza vaccine for that year did more mitigation than eliminating the disease.

You also may be interested in...

Got Your 6 - June 16, 2021

Video
6/16/2021

‘Got Your 6’ is TRICARE’s COVID vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability.

Recommended Content:

COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Get to Know the COVID-19 Vaccines - Main Infographic

Infographic
6/9/2021
An infographic describing the COVID-19 Vaccines, How they Work and Safety Monitoring Processes

This infographic pulls all three COVID-19 topics together in one graphic: Getting to Know the COVID-19 Vaccines, How they Work and Safety Monitoring

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

How COVID-19 Vaccines Work

Infographic
6/9/2021
Describes how the mRNA and viral vector vaccines work to educate beneficiaries about the COVID-19 vaccines.

This graphic showing how the mRNA and viral vector vaccines work to educate beneficiaries about the COVID-19 vaccines. Graphics are informational and provide facts on how they work in our bodies.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Get to Know the COVID-19 Vaccines

Infographic
6/9/2021
Assures beneficiaries that the COVID-19 vaccines will not give you the virus, does not affect our DNA, and is safe.

This graphic that assures beneficiaries that the vaccines will not give you the virus, does not affect our DNA, and is safe. Graphics include a person receiving the vaccine and a comparison graphic of COVID-19 trials versus other trials.

Recommended Content:

Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

COVID-19 Vaccines Safety Monitoring

Infographic
6/9/2021
Graphic that assures beneficiaries that the COVID-19 vaccines are monitored for safety. Has information on how they are being reviewed. Graphics include doctors in a laboratory and a doctor with a shield fending off the virus. The MHS and TRICARE logos are on the bottom right.

Graphic that assures beneficiaries that the COVID-19 vaccines are monitored for safety. Has information on how they are being reviewed. Graphics include doctors in a laboratory and a doctor with a shield fending off the virus.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

Get to Know the COVID-19 Vaccines (Combined)

Publication
6/9/2021

The Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines were developed to prevent infection from the virus that causes COVID-19. Learn about the vaccines, how they work and safety precautions.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | Getting the COVID-19 Vaccine | COVID-19 Vaccine Efforts

Get to Know the COVID-19 Vaccines

Publication
6/9/2021

The Pfizer-BioNTech, Moderna, and Janssen (Johnson & Johnson) COVID-19 vaccines were developed to prevent infection from the virus that causes COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

How COVID-19 Vaccines Work

Publication
6/9/2021

Learn how the different COVID-19 vaccines work.

Recommended Content:

COVID-19 Vaccine Toolkit | Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

COVID-19 Vaccine Safety Monitoring

Publication
6/9/2021

The FDA and CDC continue to monitor the safety of COVID-19 vaccines. CDC has an independent group of experts that reviews all the safety data as it comes in and provides regular safety updates.

Recommended Content:

Get to Know the COVID-19 Vaccines | COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts | Getting the COVID-19 Vaccine

VAX Facts about Getting the COVID Vaccine at the Same Time as Others

Publication
6/9/2021

Printable PDF of VAX Fact Infographic

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vax Facts

Got Your 6 - June 6, 2021

Video
6/7/2021
Video screen image for the June 6, 2021 Got Your Six video

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Facemask Required

Infographic
6/4/2021
COVID-19 poster showing doctors and patients in a health care setting wearing masks. The sign reads, "Masks are required in health care settings even if you're fully vaccinated. Please make sure your mask is on."

While the CDC relaxed mask requirements for vaccinated people, you're still required to wear masks in health care settings. Print this poster and put it around your facility to let patients and visitors know the requirements.

Recommended Content:

COVID-19 Vaccine Toolkit

Army’s 773rd administers mobile COVID-19 testing during DEF21

Article
6/4/2021
Three military personnel, wearing masks and lab coats, pose for a picture in an Albanian lab.

Approximately 800 Army Reserve soldiers from the U.S. and Europe participated in DEFENDER-Europe 21.

Recommended Content:

Health Readiness | Coronavirus | COVID-19 Vaccine Toolkit | Readiness Capabilities

Mental Health Panel Discusses Impact of COVID-19

Article
6/3/2021
Military personnel wearing face mask speaking on a panel

Walter Reed Bethesda hosts mental health panel to discuss the impacts of COVID-19.

Recommended Content:

COVID-19 Vaccine Toolkit | Mental Health Awareness Month | Coronavirus | Psychological Fitness

Based on data, MHS experts encourage vaccines for adolescents

Article
6/1/2021
Sister and brother smiling at each other

With the Pfizer vaccine approved for youth ages 12 to 15, MHS adolescents are lining up to get the COVID-19 vaccine.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | Children's Health | Vaccine Eligibility
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 40

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.